TGFB1 and neoplasm: Similar therapeutic benefits were observed in multiple murine mesothelioma tumor models following administration of a soluble TGFβRII chimeric protein designed to neutralize TGFβ1 (and TGFβIII) and thereby abrogate its signaling in target cells.